Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to show a fall in quarterly revenue when it reports results on February 27 for the period ending December 31 2024
The San Diego California-based company is expected to report a 39.6% decrease in revenue to $94.17 thousand from $156 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cardiff Oncology Inc is $11.50, above its last closing price of $4.56.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.27 | -0.27 | -0.25 | Beat | 7.4 |
Jun. 30 2024 | -0.25 | -0.26 | Missed | -5.1 | |
Mar. 31 2024 | -0.25 | -0.25 | -0.22 | Beat | 11.1 |
Dec. 31 2023 | -0.27 | -0.28 | -0.21 | Beat | 24.3 |
Sep. 30 2023 | -0.28 | -0.28 | -0.22 | Beat | 22.8 |
Jun. 30 2023 | -0.28 | -0.26 | -0.25 | Beat | 3.5 |
Mar. 31 2023 | -0.22 | -0.23 | -0.25 | Missed | -10.6 |
Dec. 31 2022 | -0.22 | -0.23 | -0.20 | Beat | 14.9 |
This summary was machine generated February 25 at 22:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。